Do new biologics meet the unmet medical need in rheumatoid arthritis? Safety and efficacy of abatacept following B-cell depletion

Walker, Ulrich A; Courvoisier, Delphine S; Dudler, Jean; Aeberli, Daniel; von Kempis, Johannes; Scherer, Almut; Finckh, Axel; on behalf of the, Swiss Clinical Quality Management Programme in Rheumatic Disease (2011). Do new biologics meet the unmet medical need in rheumatoid arthritis? Safety and efficacy of abatacept following B-cell depletion. Rheumatology, 50(1), pp. 243-244. Oxford: Oxford University Press 10.1093/rheumatology/keq258

[img]
Preview
Text
keq258.pdf - Published Version
Available under License Publisher holds Copyright.

Download (37kB) | Preview

Sir, anti TNF-α agents (aTNFs) are the most commonly prescribed biological agents in RA. More recently abatacept (ABA), a T-cell costimulation modulator, and rituximab (RTX), a monoclonal antibody directed against CD20, have become available. Observational studies suggest that switching to a new drug class may be more effective in uncontrolled RA than switching to a class of biologics to which the patient had unsuccessfully been exposed [1]. Information about the efficacy and safety of cycling strategies through third-line biologics is lacking. This study aimed to analyse the effectiveness and safety of switching patients to ABA as the third biological class after failure of aTNF plus RTX.

The Swiss Clinical Quality Management (SCQM) programme for RA is a longitudinal population-based cohort, which has been approved by the local ethics committees of all participating centres [2]. For this analysis, we collected all the …

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Rheumatology and Immunology

UniBE Contributor:

Aeberli, Daniel

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1462-0324

Publisher:

Oxford University Press

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:10

Last Modified:

05 Dec 2022 14:01

Publisher DOI:

10.1093/rheumatology/keq258

PubMed ID:

20716674

Web of Science ID:

000285193500033

BORIS DOI:

10.7892/boris.1640

URI:

https://boris.unibe.ch/id/eprint/1640 (FactScience: 203422)

Actions (login required)

Edit item Edit item
Provide Feedback